TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02357303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone
Description: 100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Description: 100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL of water
Study: NCT01450345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
Study: NCT00688714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6482
Description: 0,9-364,5 mg administrated through intravenous infusion over 3 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02225535

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NP face to face management of Chronic Low Back Pain
Description: usual NP management of chronic low back disorder
Study: NCT03276104

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IOL repositioning
Description: Intraocular lens repositioning by scleral suturing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IOL exchange
Description: Intraocular lens exchange with retropupillary iris-claw lens
Study: NCT02225535

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PT face to face management of Chronic Low Back Pain
Description: Includes manual therapy, education, exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interprofessional Videoconferencing for Chronic Low Back Pain
Description: Includes manual therapy, education, exercise.
Study: NCT01226108

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patch
Description: One patch per day, Duration: three weeks, Administration: behind the ear~--------------------------------------------------------------------------------
Study: NCT02092714

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02347384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta PLUS Femoral Head + SL-TWIN Stem
Description: Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head \& SL-TWIN Stem

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOLOX forte ball head + SL-PLUS Stem
Description: Subject will undergo total hip arthroplasty with BIOLOX forte ball head \& SL-PLUS Stem
Study: NCT03778801

Intervention type: DIAGNOSTIC_TEST
Intervention: fibromyalgia syndrome and chronic neck pain
Description: We assessed pain intensity, kinesiophobia, fatigue, depression, physical activity level and disability in patients with fibromyalgia syndrome and chronic neck pain, and healthy individuals in this cross-sectional study.

Intervention type: DIAGNOSTIC_TEST
Intervention: fibromyalgia syndrome and chronic neck pain
Description: We assessed pain intensity, kinesiophobia, fatigue, depression, physical activity level and disability in patients with fibromyalgia syndrome and chronic neck pain, and healthy individuals in this cross-sectional study.
Study: NCT02940704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc
Description: * Canals will be instrumented using Reciproc reciprocating system set on an electric motor, with adjusted torque and speed according to the manufacturer's instructions.~* There is no need for coronal preflaring with a Gates Glidden drill or an orifice opener since the design of the Reciproc instrument allows any obstructions in the coronal third to be removed, as claimed by the manufacturer.~* Reciproc file selection: R40 (40/0.06) is to be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One Shape
Description: * Coronal preflaring will be performed using Gates Glidden drill.~* Canals will be instrumented using One Shape single-file (25/0.06) set on an electric motor with adjusted torque and speed according to the manufacturer's instructions.~* For wide canals, One Shape Apical (30/0.06, 37/0.06) will be used.
Study: NCT00369824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Different formulations of GSK Biologicals' HPV vaccine (580299)
Description: Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Different formulations of GSK Biologicals' HPV vaccine (580299)
Description: Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Different formulations of GSK Biologicals' HPV vaccine (580299)
Description: Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively
Study: NCT02662530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined either by visual/clinical or by biomechanical analysis of dystonic movements for cervical dystonia therapy in neck and shoulder muscles every 12 weeks over 30 weeks. BoNT-A dose will range from 50-300 U.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined either by visual/clinical or by biomechanical analysis of dystonic movements for cervical dystonia therapy in neck and shoulder muscles every 12 weeks over 30 weeks. BoNT-A dose will range from 50-300 U.
Study: NCT04393246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Regular standard of care for COVID-19 patients
Study: NCT05119023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observational Learning
Description: All participants will complete a computer-based serial response time task intended to measure observational (implicit) learning ability. In this task, participants look at a dot move from one of 4 positions on a computer screen. Unbeknownst to participants, dot movement followed a 12-movement pattern for most experimental blocks. Eye-tracking data is collected and eye fixations within regions of interest trigger trial advancement. Learning ability is evaluated as a comparison of saccadic response times during sequenced trials relative to pseudorandomized trials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rule-based Learning
Description: All participants will complete a computer-based rule-based learning task intended to measure rule-based (explicit) learning ability. In this task, participants look at sequences of geometric shapes on a computer screen. Through visuals and verbal instruction, they are taught 5 rules that govern sequences. After learning rules, participants are asked to judge via button press whether novel sequences adhere to rules or not.
Study: NCT00481390

Intervention type: PROCEDURE
Intervention: Cheek cells sample
Description: Cheek cells sample

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample
Study: NCT00661648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)
Description: artificial pancreas
Study: NCT00756730

Intervention type: DRUG
Group type: OTHER
Intervention: ATV/r
Description: Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.

Intervention type: DRUG
Group type: OTHER
Intervention: DRV/r
Description: We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
Study: NCT02129049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Participate in the Enhancing Connections Telephone Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Participate in the Enhancing Connections Telephone Program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT02798835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block
Description: Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block with dexamethasone
Description: Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal catheter
Description: Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Used in spinal anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Used in spinal anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Used in spinal anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: May or may not be used in spinal anesthetic
Study: NCT02896907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given IV
Study: NCT02867345

Intervention type: BIOLOGICAL
Intervention: PD-1 Knockout T Cells
Description: PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).

Intervention type: DRUG
Intervention: IL-2
Description: Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).

Intervention type: DRUG
Intervention: IL-2
Description: Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
Study: NCT00518219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TW
Description: TW,120mg/d
Study: NCT05909605

Intervention type: DEVICE
Intervention: sphygmomanometer
Description: Comparison to the ultrasound sensor

Intervention type: DEVICE
Intervention: Arterial Line
Description: Comparison to the ultrasound sensor
Study: NCT04359082

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CocoaVia supplement
Description: CocoaVia is a dietary supplement that has concentrated bioflavanols of 225 mg flavanols per pill along with 30 mg theobromine and 10 mg caffeine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Description: Placebo pill has no bioflavanols with 30 mg theobromine and 10 mg caffeine
Study: NCT02922634

Intervention type: OTHER
Intervention: Mini Cog
Description: short cognitive screen, short Frailty screen
Study: NCT03824925

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral Zinc capsule
Description: Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral Zinc capsule
Description: Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zinc Sulfate 220 MG
Description: Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate 220 MG
Description: Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc
Study: NCT00418834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe and atorvastatin
Description: ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (unspecified)
Description: Placebo (unspecified) daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (unspecified)
Description: Placebo (unspecified) daily for 12 weeks
Study: NCT01996306

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPT-11 (Irinotecan)
Description: 150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
Study: NCT02798835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: May or may not be used in spinal anesthetic
Study: NCT01584531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib
Description: Rigosertib sodium will be available as soft gel capsules in strengths of 280 mg and 70 mg. Rigosertib will be administered on an outpatient basis.~Patients will take a 560 mg dose (e.g., 2 x 280 mg capsules) of oral rigosertib in the morning and 280 mg dose (e.g., 1 x 280 mg capsules) of oral rigosertib every day of 21-day cycles. Rigosertib should be taken in a fasting state (defined by at least 30 minutes before next meal) BID at 12 hr intervals (with a window of 2 hr). Any vomited dose will be reported as a missed dose.~The patient will fill a diary indicating the day and time of drug intake.
Study: NCT02237742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: Intravenous, 100 micrograms, single dose, 30 minute infusion
Study: NCT02842463

Intervention type: OTHER
Intervention: 2 times : 6-minute stepper test with a rest of 20min between each test.
Study: NCT03740620

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bevel facing the cephalad direction of the patient
Description: The bevel of the nasotracheal tube facing cephalad direction of the patient

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bevel facing leftward of the patient
Description: The bevel of the nasotracheal tube facing the left side of the patient
Study: NCT01878721

Intervention type: RADIATION
Intervention: PET/CT
Description: positron emission tomography/computed tomography

Intervention type: RADIATION
Intervention: PET/CT
Description: positron emission tomography/computed tomography

Intervention type: RADIATION
Intervention: PET/CT
Description: positron emission tomography/computed tomography

Intervention type: RADIATION
Intervention: PET/CT
Description: positron emission tomography/computed tomography

Intervention type: RADIATION
Intervention: PET/CT
Description: positron emission tomography/computed tomography
Study: NCT05039437

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MGF-4
Description: Participants were instructed to take 2 capsules of MGF-4 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MGF-7
Description: Participants were instructed to take 2 capsules of MGF-7 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
Study: NCT03680079

Intervention type: OTHER
Group type: OTHER
Intervention: Group education sessions
Description: Peer support and interaction both in-person during group education sessions and online via social media platforms
Study: NCT03971578

Intervention type: OTHER
Intervention: No Intervention Provided
Description: No Intervention Provided

Intervention type: OTHER
Intervention: No Intervention Provided
Description: No Intervention Provided
Study: NCT03275584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-13 ammonia intravenous injection
Description: Participants will receive two injections of N-13 ammonia, once at rest and once at stress before undergoing positron emission tomography myocardial perfusion imaging
Study: NCT00149149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zinc Carnosine coadministered with Indomethacin
Study: NCT03778801

Intervention type: DIAGNOSTIC_TEST
Intervention: fibromyalgia syndrome and chronic neck pain
Description: We assessed pain intensity, kinesiophobia, fatigue, depression, physical activity level and disability in patients with fibromyalgia syndrome and chronic neck pain, and healthy individuals in this cross-sectional study.
Study: NCT03540680

Intervention type: OTHER
Group type: OTHER
Intervention: Blood punction
Description: For the arms Term newborns (≥37GA) and Premature newborns the only intervention is a blood punction on the cordon.~For the arms Child between 7 and 15 years old with or without BPD the only intervention is a blood punction on peripheral blood.
Study: NCT01996306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU Bolus
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
Study: NCT00149149

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo coadministered with Indomethacin
Study: NCT03540680

Intervention type: OTHER
Group type: OTHER
Intervention: Blood punction
Description: For the arms Term newborns (≥37GA) and Premature newborns the only intervention is a blood punction on the cordon.~For the arms Child between 7 and 15 years old with or without BPD the only intervention is a blood punction on peripheral blood.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood punction
Description: For the arms Term newborns (≥37GA) and Premature newborns the only intervention is a blood punction on the cordon.~For the arms Child between 7 and 15 years old with or without BPD the only intervention is a blood punction on peripheral blood.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood punction
Description: For the arms Term newborns (≥37GA) and Premature newborns the only intervention is a blood punction on the cordon.~For the arms Child between 7 and 15 years old with or without BPD the only intervention is a blood punction on peripheral blood.
Study: NCT00743470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: lopinavir/ritonavir tablet; see arm for intervention description
Study: NCT02798835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: May or may not be used in spinal anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: To be given intravenously at time of nerve block to one of the study arms.
Study: NCT01081145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Guanfacine Hydrochloride
Description: The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
Study: NCT01315314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balance, Fresenius Medical Care, Germany
Description: low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)